Recent therapeutic advancements in uncontrolled CRSwNP have introduced biologic medications, including monoclonal antibodies targeting the key type 2 inflammatory mediators IL-4Rα, IgE, and IL-5, with established guidelines for prescription and evaluation [1,11]. The gene discussed is IL4R; the disease is chronic rhinosinusitis with nasal polyps.